Organization
Centre Francois Baclesse
9 clinical trials
1 abstract
Clinical trial
Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas PatientsStatus: Recruiting, Estimated PCD: 2024-09-13
Abstract
Multiplex analysis of the immune environment before and after neoadjuvant durvalumab as a prognostic factor in resectable non-small cell lung cancer (NSCLC) in the IFCT-1601 IONESCO phase 2 trial.Org: Service de Pneumologie et oncologie thoracique, CIC Inserm 1425, Centre Francois Baclesse, Hôpital Gabriel Montpied, Centre Hospitalier Du Mans,
Clinical trial
Prognostic Impact of the Neutrophil/Lymphocyte Ratio (NLR) in the Treatment of First-line Metastatic or Locally Advanced Breast Cancer Treated With CDK4/6 inStatus: Active (not recruiting), Estimated PCD: 2025-06-01
Clinical trial
Impact of Applying a Bandage Skin Hydrogel on the Pains of the Head and Neck in Patients With Cancer of Head and Neck Treated With RadiotherapyStatus: Completed, Estimated PCD: 2022-10-01
Clinical trial
A Randomized Phase II Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma MetastasesStatus: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial Carcinoma: A Single-arm Phase 2 TrialStatus: Recruiting, Estimated PCD: 2023-07-28
Clinical trial
A Phase II Study Assessing Safety and Efficacy of Cabozantinib for Advanced or Metastatic Cervical Carcinoma After Platinum Treatment FailureStatus: Completed, Estimated PCD: 2023-01-15
Clinical trial
A Multicentre Phase II, Open-label, Non-randomized Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/- Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted TherapiesStatus: Recruiting, Estimated PCD: 2021-10-22
Clinical trial
Multicentric Phase III Trial Comparing Two Strategies in Intermediate-risk Differentiated Thyroid Cancer Patients: Systematic Radioiodine Administration Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up Based on Serum Tg Values and Diagnostic RAI ScintigraphyStatus: Recruiting, Estimated PCD: 2031-02-01